摘要
目的:评价洛铂联合伊立替康治疗广泛期小细胞肺癌的临床疗效和安全性。方法:洛铂35mg/m2第1天,伊立替康80mg/m2第1、8天,每21d为一周期,每2个周期结束复查影像学资料行疗效评价,治疗既往未接受过化疗的广泛期小细胞肺癌25例。结果:25例患者均可评价疗效,完全缓解(CR)1例,部分缓解(PR)9例,稳定(SD)7例,进展(PD)8例。客观缓解率(ORR)40%,疾病控制率(DCR)68%,中位无进展生存期(PFS)5.3个月,中位生存期(OS)7.6个月,主要毒副反应为血液学毒性及消化道反应。结论:洛铂联合伊立替康方案作为广泛期SCLC化疗有较好的疗效,毒副反应可以耐受。
AIM： To investigate the effects and side effects of Lobaplatin plus Irinotecan regimens in the treatment of patients suffered from extensive stage disease small-cell lung cancer （ED-SCLC）. METHODS： 25 patients suffered from ED-SCLC were treated by Loba- platin 35 mg/m2 i. v. dl plus Irinotecan 80 mg/ m2 i. v. dl,8 ,every 3 weeks. Efficacy was esti mated by imaging every 2 cycles. RESULTS：In 25 evaluable patients, CR was 4% （1/25）,PR was 36% （9/25）, SD was 28%（7/25）, and PD was 32G （8/25）. The objective response rate （ORR） was 40G . The disease control rate （DCR） was 68O/oo. The median progression free survival （PFS） was 5.3 months. The median o- verall survival（OS） was 7.6 months. The most commonly seen adverse events（AEs） were my- elosuppression and diarrhea. There was no treatment-related death. CONCLUSION： The treatment of Lobaplatin plus Irinotecan shows an effective antitumor activity and a favorable toxicity profile in patients with ED-SCLC.
出处
《中国临床药理学与治疗学》
CAS
CSCD
2013年第9期1049-1052,共4页
Chinese Journal of Clinical Pharmacology and Therapeutics
关键词
小细胞肺癌
洛铂
伊立替康
Small-cell lung cancer
Lobaplatin
Irinotecan
